-
1.发明申请COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CANCER BY TARGETING AND INHIBITING CANCER STEM CELLS 审中-公开通过靶向和抑制癌症干细胞治疗和预防癌症的组合物和方法公开(公告)号：US20130129809A1
公开(公告)日：2013-05-23
申请号：US13476840
申请日：2012-05-21
IPC分类号： A61K31/7068 , A61K31/122 , A61K31/366 , A61K31/05 , A61K45/06 , A61K31/105 , A61K31/353 , A61K31/26 , A61K31/167 , A61K31/352 , A61K31/12
CPC分类号： A61K31/7068 , A61K31/05 , A61K31/10 , A61K31/105 , A61K31/12 , A61K31/122 , A61K31/166 , A61K31/167 , A61K31/26 , A61K31/352 , A61K31/353 , A61K31/366 , A61K31/4406 , A61K31/4741 , A61K31/517 , A61K31/53 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： The invention relates to compositions and methods for treating cancer comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, methods of inhibiting the growth of cancer stem cells or tumor initiating cell comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, and methods of enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells comprising administering to a subject in need a pharmaceutically effective dose of a chemotherapeutic drug and a pharmaceutically effective dose of a cancer stem cell inhibitor.
摘要翻译： 本发明涉及用于治疗癌症的组合物和方法，其包括向需要的受试者施用药学有效剂量的癌症干细胞抑制剂，抑制癌症干细胞或肿瘤起始细胞生长的方法，包括向需要的受试者施用药学上 癌症干细胞抑制剂的有效剂量，以及增强化学治疗药物或辐照对癌细胞的生物学作用的方法，其包括向有需要的受试者施用药物有效剂量的化学治疗药物和药物有效剂量的癌症干细胞抑制剂 。
-
公开(公告)号：US20190330165A1
公开(公告)日：2019-10-31
申请号：US16397345
申请日：2019-04-29
IPC分类号： C07D253/07 , C07D253/06 , A61K45/06 , A61K31/53 , C07D403/06 , C07D417/06 , C07D413/06
摘要： This invention is directed to compositions, methods and kits that can be used for reducing cell viability, inducing cell apoptosis, and inhibiting cell proliferation, such as for the treatment of cancer. The invention is also directed to compositions, methods and kits that can be used for treating inflammatory conditions, such as by modulating inflammatory cytokines.
-
3.发明申请METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS 审中-公开TRAIL-DEATH受体激动剂/激活剂的方法和组合公开(公告)号：US20110172234A1
公开(公告)日：2011-07-14
申请号：US13073665
申请日：2011-03-28
IPC分类号： A61K31/5377 , C12N5/00 , A61K31/5025 , A61K31/497 , A61K31/4152 , A61K31/427 , A61K31/44 , A61K31/37 , A61K31/4192 , A61K31/433 , A61K31/415 , A61K31/4184 , A61K31/194 , A61K31/522 , A61K31/421 , A61K31/137 , A61P35/00
CPC分类号： A61K31/41 , A61K31/192
摘要： This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
摘要翻译： 本发明描述了一系列用于预防和治疗诸如癌症的疾病的方法和组合物。 本发明的一个方面描述了可以用于结合死亡受体TRAIL-R1 / DR4和/或TRAIL-R2 / DR5的小分子基药物，并在保护正常细胞的同时诱导癌细胞凋亡。 本发明还描述了TRAIL死亡受体激动剂/激活剂（DRA）及其用途，例如通过胱天蛋白酶-8诱导凋亡和胱天蛋白酶-3激活。 本发明还描述了使用DRAs作为单药治疗或治疗癌症的方法，例如乳腺癌，前列腺癌，结肠癌，胰腺癌，卵巢癌，肺癌和脑癌，白血病，淋巴瘤，多发性骨髓瘤和间皮瘤。 结合其他疗法。
-
4.发明授权公开(公告)号：US07915245B2
公开(公告)日：2011-03-29
申请号：US11866162
申请日：2007-10-02
CPC分类号： A61K31/41 , A61K31/192
摘要： This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
摘要翻译： 本发明描述了一系列用于预防和治疗诸如癌症的疾病的方法和组合物。 本发明的一个方面描述了可以用于结合死亡受体TRAIL-R1 / DR4和/或TRAIL-R2 / DR5的小分子基药物，并在保护正常细胞的同时诱导癌细胞凋亡。 本发明还描述了TRAIL死亡受体激动剂/激活剂（DRA）及其用途，例如通过胱天蛋白酶-8诱导凋亡和胱天蛋白酶-3激活。 本发明还描述了使用DRAs作为单药治疗或治疗癌症的方法，例如乳腺癌，前列腺癌，结肠癌，胰腺癌，卵巢癌，肺癌和脑癌，白血病，淋巴瘤，多发性骨髓瘤和间皮瘤。 结合其他疗法。
-
5.发明申请公开(公告)号：US20080214547A1
公开(公告)日：2008-09-04
申请号：US11866162
申请日：2007-10-02
IPC分类号： A61K31/5377 , A61P35/00 , A61K31/135 , A61K31/196 , A61K31/4155 , A61K31/5025 , A61K31/433 , A61K31/421 , A61K31/519 , A61K31/4192 , A61K31/497 , A61K31/415 , A61K31/427 , A61K31/44
CPC分类号： A61K31/41 , A61K31/192
摘要： This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
摘要翻译： 本发明描述了一系列用于预防和治疗诸如癌症的疾病的方法和组合物。 本发明的一个方面描述了可以用于结合死亡受体TRAIL-R1 / DR4和/或TRAIL-R2 / DR5的小分子基药物，并在保护正常细胞的同时诱导癌细胞凋亡。 本发明还描述了TRAIL死亡受体激动剂/激活剂（DRA）及其用途，例如通过胱天蛋白酶-8诱导凋亡和胱天蛋白酶-3激活。 本发明还描述了使用DRAs作为单药治疗或治疗癌症的方法，例如乳腺癌，前列腺癌，结肠癌，胰腺癌，卵巢癌，肺癌和脑癌，白血病，淋巴瘤，多发性骨髓瘤和间皮瘤。 结合其他疗法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
